1. Phylogeny  
Bruton’s tyrosine kinase (BTK) is a member of the Tec family of non‐receptor tyrosine kinases, a group that also includes inducible T cell kinase (ITK), bone marrow tyrosine kinase on chromosome X (BMX), TEC, and TXK, and it is evolutionarily conserved across vertebrate species, with orthologs identified in mammals, birds, and amphibians (singh2018roleofbruton’s pages 2-4). BTK shares a common ancestry with other kinases that emerged early in the evolution of eukaryotes, and its placement within the kinome was established by large-scale analyses that characterized the complement of human kinases (mcdonald2021theroleof pages 1-2). As part of the Tec family, BTK occupies a distinct phylogenetic niche relative to the large families such as the Src, AGC, and CMGC kinases, and its domain organization distinguishes it from receptor tyrosine kinases and other non‐receptor classes (hendriks2014targetingbrutonstyrosine pages 5-6).

2. Reaction Catalyzed  
BTK catalyzes the transfer of the γ-phosphate group from adenosine triphosphate (ATP) to specific tyrosine residues on target proteins, a reaction critical for transducing signals in B-cell receptor (BCR) and other immunoreceptor pathways (buggy2012brutontyrosinekinase pages 1-3). The general reaction can be written as follows: ATP + [protein]-tyrosine → ADP + [protein]-phosphotyrosine + H⁺, reflecting its role as an ATP-dependent tyrosine kinase (wen2021inhibitorstargetingbruton’s pages 1-2).

3. Cofactor Requirements  
The catalytic activity of BTK is dependent on the presence of divalent metal ions, with magnesium (Mg²⁺) serving as an essential cofactor that coordinates ATP binding and facilitates the phosphoryl transfer reaction (xing2014brutonstkinhibitors pages 1-2).

4. Substrate Specificity  
BTK exhibits substrate specificity for proteins that contain target tyrosine residues within a context amenable to phosphorylation; a well‐characterized substrate in B-cell signaling is phospholipase C gamma 2 (PLCγ2), which is phosphorylated at multiple tyrosine sites following B-cell receptor engagement (buggy2012brutontyrosinekinase pages 3-4). Although consensus substrate motifs for many tyrosine kinases have been defined through systematic studies, BTK’s physiological substrates include adapter proteins such as BLNK and signaling regulators such as TIRAP, with recognition likely involving structural determinants in addition to local amino acid context (zain2021structurefunctionrelationshipsof pages 7-9). Its substrate specificity is further underscored by the ability of BTK to phosphorylate components in both the BCR and Toll-like receptor (TLR) signaling pathways, thus modulating downstream effectors such as NF-κB (singh2018roleofbruton’s pages 2-4).

5. Structure  
The overall structure of BTK is characterized by a modular domain organization that includes an N-terminal pleckstrin homology (PH) domain, a Tec homology (TH) domain that contains a zinc-binding motif, followed by Src homology (SH3 and SH2) domains, and a C-terminal kinase domain responsible for catalytic function (lou2012bruton’styrosinekinase pages 9-10, xing2014brutonstkinhibitors pages 2-3). The PH domain plays a critical role in targeting BTK to the plasma membrane by binding to phosphoinositides such as PIP₃, and this membrane localization is necessary for its activation by upstream kinases (buggy2012brutontyrosinekinase pages 1-3). Within the kinase domain, key structural features include the activation loop—which contains the tyrosine residue Y551, whose phosphorylation is essential for kinase activation—and an autophosphorylation site at Y223 located in the SH3 domain; the catalytic cleft also harbors a cysteine residue at position 481 that is a critical target for covalent inhibitors such as ibrutinib (xing2014brutonstkinhibitors pages 18-19, schnute2012brutonstyrosinekinase pages 3-6). The enzyme exhibits conformational flexibility with regions such as the αC-helix and the DFG motif adopting different orientations in the active versus inactive states, and crystal structures of the kinase domain have illustrated an “αC-helix-out” inactive conformation that is stabilized in part by disruptions of key salt bridges (xing2014brutonstkinhibitors pages 19-20).

6. Regulation  
The activity of BTK is tightly regulated by numerous mechanisms, predominantly through phosphorylation events and protein-protein interactions. Phosphorylation of Y551 in the kinase domain—catalyzed by upstream kinases such as SYK or members of the Src family (e.g., LYN)—induces a conformational change that markedly increases BTK’s catalytic activity (buggy2012brutontyrosinekinase pages 3-4). Following this event, BTK undergoes autophosphorylation at Y223 within its SH3 domain, which further stabilizes its active conformation and promotes propagation of downstream signaling via substrates like PLCγ2 (singh2018roleofbruton’s pages 2-4, wen2021inhibitorstargetingbruton’s pages 1-2). In addition to phosphorylation, BTK functions as a scaffold protein that nucleates various multiprotein complexes involved in B-cell and Toll-like receptor signaling; for instance, it induces tyrosine phosphorylation of the TIR domain-containing adaptor protein (TIRAP), thereby triggering its degradation and fine-tuning TLR9-mediated signaling (buggy2012brutontyrosinekinase pages 9-11). Moreover, BTK is implicated in the activation of the NLRP3 inflammasome through phosphorylation of NLRP3, a process that is central to the regulation of innate immune responses (mcdonald2021theroleof pages 22-25). Together, these regulatory events coordinate the spatiotemporal activity of BTK, ensuring that it is activated in response to appropriate antigen receptor engagement and modulated during stress and inflammatory conditions (crofford2016theroleof pages 9-10, hendriks2014targetingbrutonstyrosine pages 11-12).

7. Function  
BTK plays an indispensable role in both the adaptive and innate branches of the immune system. In B lymphocytes, BTK is essential for transmitting signals from the B-cell receptor (BCR) upon antigen engagement, thereby facilitating B-cell development, proliferation, differentiation, and survival (buggy2012brutontyrosinekinase pages 1-3, singh2018roleofbruton’s pages 1-2). Its activation leads to the phosphorylation of PLCγ2, which in turn catalyzes the production of second messengers that mobilize intracellular calcium and subsequently activate protein kinase C (PKC) family members; these events culminate in the activation of transcription factors such as NF-κB that regulate the expression of genes critical for B-cell function (buggy2012brutontyrosinekinase pages 3-4, wen2021inhibitorstargetingbruton’s pages 1-2). Beyond its role in BCR signaling, BTK is also a key component of signaling pathways initiated by Toll-like receptors (TLRs), where it influences the production of cytokines and type I interferons through its modulation of NF-κB and IRF-dependent gene transcription (mcdonald2021theroleof pages 2-5, weber2017bruton’styrosinekinase pages 1-2). Additionally, BTK is involved in the assembly and activation of the NLRP3 inflammasome, thereby playing a role in the regulation of inflammatory responses and programmed cell death (zain2021structurefunctionrelationshipsof pages 9-9). In the context of transcription regulation, BTK contributes indirectly by transiently phosphorylating transcription factors such as GTF2I, which then translocates to the nucleus and modulates gene enhancer activity, and it is required for the formation of functional ARID3A DNA-binding complexes, further influencing the transcriptional landscape of immune cells (buggy2012brutontyrosinekinase pages 9-11). Expression of BTK is predominantly observed in hematopoietic cells, especially B cells, mast cells, monocytes, and macrophages, while its expression is negligible in T lymphocytes and terminally differentiated plasma cells; this restricted expression pattern underscores its specialized role in adaptive immunity and the fine regulation of innate immune responses (crofford2016theroleof pages 16-21, hendriks2014targetingbrutonstyrosine pages 1-2).

8. Other Comments  
Several potent inhibitors of BTK have been developed based on its structural and functional profiles, notably the irreversible covalent inhibitor ibrutinib, which binds to the cysteine residue at position 481 within the ATP-binding pocket, leading to sustained inhibition of BTK activity in B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) (xing2014brutonstkinhibitors pages 16-18, weber2017bruton’styrosinekinase pages 2-4). Second-generation inhibitors, including acalabrutinib and zanubrutinib, have been introduced with the aim of improving selectivity and reducing off-target effects while retaining clinical efficacy (wen2021inhibitorstargetingbruton’s pages 1-2, ringheim2021bruton’styrosinekinase pages 1-2). Mutations within BTK, such as those affecting its critical catalytic residues, are known to result in immunodeficiency disorders like X-linked agammaglobulinemia (XLA), while dysregulation or overactivation of BTK contributes to the pathogenesis of a wide range of B-cell malignancies and autoimmune diseases (buggy2012brutontyrosinekinase pages 1-3, singh2018roleofbruton’s pages 17-17). In addition to its inhibitor-based therapeutic applications, BTK’s role in linking signals from both the BCR and TLR pathways as well as its involvement in the regulation of the NLRP3 inflammasome highlight its potential as a broader target for modulating inflammatory responses in diseases such as rheumatoid arthritis and systemic lupus erythematosus (mcdonald2021theroleof pages 22-25, schnute2012brutonstyrosinekinase pages 8-11). Ongoing research into the precise substrate specificities, allosteric regulatory mechanisms, and interaction networks of BTK continues to provide a deeper understanding of its multifaceted roles in immune cell signaling (zain2021structurefunctionrelationshipsof pages 1-2, rozkiewicz2023bruton’styrosinekinase pages 3-5).

9. References  
1. Buggy, J. J. & Elias, L. (2012). Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. International Reviews of Immunology, 31:119-132. (buggy2012brutontyrosinekinase pages 1-3, buggy2012brutontyrosinekinase pages 3-4, buggy2012brutontyrosinekinase pages 9-11, buggy2012brutontyrosinekinase pages 11-12)  
2. Crofford, L. J., Nyhoff, L. E., Sheehan, J. H., & Kendall, P. L. (2016). The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Expert Review of Clinical Immunology, 12:763-773. (crofford2016theroleof pages 1-3, crofford2016theroleof pages 9-10, crofford2016theroleof pages 16-21)  
3. Dinh, M. et al. (2007). Activation mechanism and steady state kinetics of Bruton’s tyrosine kinase. Journal of Biological Chemistry, 282:8768-8776. (dinh2007activationmechanismand pages 8-8)  
4. Feng, Y. et al. (2019). Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). Expert Opinion on Therapeutic Patents, 29:217-241. (feng2019bruton’styrosinekinase pages 1-7, feng2019bruton’styrosinekinase pages 25-30, feng2019bruton’styrosinekinase pages 43-50)  
5. Hendriks, R., Yuvaraj, S., & Kil, L. P. (2014). Targeting Bruton's tyrosine kinase in B-cell malignancies. Nature Reviews Cancer, 14:219-232. (hendriks2014targetingbrutonstyrosine pages 1-2, hendriks2014targetingbrutonstyrosine pages 5-6, hendriks2014targetingbrutonstyrosine pages 11-12)  
6. Kueffer, L. E., Joseph, R. E., & Andreotti, A. H. (2021). Reining in BTK: interdomain interactions and their importance in the regulatory control of BTK. Frontiers in Cell and Developmental Biology. (kueffer2021reininginbtk pages 1-2, kueffer2021reininginbtk pages 12-12)  
7. Liang, C. et al. (2018). The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. European Journal of Medicinal Chemistry, 151:315-326. (liang2018thedevelopmentof pages 1-6)  
8. Liu, J. K. et al. (2021). Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): current development. European Journal of Medicinal Chemistry, 217:113329. (liu2021emergingsmallmoleculeinhibitors pages 1-2, liu2021emergingsmallmoleculeinhibitors pages 22-23)  
9. Lou, Y. et al. (2012). Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B-cell malignancies. Journal of Medicinal Chemistry, 55:4539-4550. (lou2012bruton’styrosinekinase pages 9-10)  
10. Marcotte, D. J. et al. (2010). Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for Tec family kinases. Protein Science. (marcotte2010structuresofhuman pages 1-3)  
11. McDonald, C. et al. (2021). The role of Bruton's tyrosine kinase in the immune system and disease. Immunology, 164:722-736. (mcdonald2021theroleof pages 1-2, mcdonald2021theroleof pages 2-5, mcdonald2021theroleof pages 5-7, mcdonald2021theroleof pages 22-25)  
12. Ratzon, E. et al. (2017). A small molecule inhibitor of Bruton's tyrosine kinase involved in B-cell signaling. ACS Omega, 2:4398-4410. (ratzon2017asmallmolecule pages 11-12)  
13. Ringheim, G. E. et al. (2021). Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Frontiers in Immunology, (ringheim2021bruton’styrosinekinase pages 1-2)  
14. Rozkiewicz, D. et al. (2023). Bruton's tyrosine kinase inhibitors (BTKis): review of preclinical studies and evaluation of clinical trials. Molecules, 28:2400. (rozkiewicz2023bruton’styrosinekinase pages 1-3, rozkiewicz2023bruton’styrosinekinase pages 3-5, rozkiewicz2023bruton’styrosinekinase pages 5-6, rozkiewicz2023bruton’styrosinekinase pages 14-15)  
15. Schnute, M. E., Huang, A., & Saiah, E. (2012). Bruton's tyrosine kinase (BTK). In Anti-Inflammatory Drug Discovery, pages 297-326. (schnute2012brutonstyrosinekinase pages 1-3, schnute2012brutonstyrosinekinase pages 3-6, schnute2012brutonstyrosinekinase pages 8-11, schnute2012brutonstyrosinekinase pages 25-27)  
16. Singh, S. P., Dammeijer, F., & Hendriks, R. W. (2018). Role of Bruton's tyrosine kinase in B cells and malignancies. Molecular Cancer, (singh2018roleofbruton’s pages 1-2, singh2018roleofbruton’s pages 2-4, singh2018roleofbruton’s pages 17-17)  
17. Weber, A. N. R. et al. (2017). Bruton's tyrosine kinase: an emerging key player in innate immunity. Frontiers in Immunology, (weber2017bruton’styrosinekinase pages 1-2, weber2017bruton’styrosinekinase pages 2-4)  
18. Wen, T. et al. (2021). Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. Leukemia, 35:312-332. (wen2021inhibitorstargetingbruton’s pages 1-2)  
19. Whang, J. A. & Chang, B. Y. (2014). Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discovery Today, 19:1200-1204. (whang2014brutonstyrosinekinase pages 1-3)  
20. Xing, L. & Huang, A. (2014). Bruton's TK inhibitors: structural insights and evolution of clinical candidates. Future Medicinal Chemistry, 6:675-695. (xing2014brutonstkinhibitors pages 1-2, xing2014brutonstkinhibitors pages 2-3, xing2014brutonstkinhibitors pages 16-18, xing2014brutonstkinhibitors pages 18-19, xing2014brutonstkinhibitors pages 19-20)  
21. Zain, R. & Vihinen, M. (2021). Structure-function relationships of covalent and non-covalent BTK inhibitors. Frontiers in Immunology, (zain2021structurefunctionrelationshipsof pages 1-2, zain2021structurefunctionrelationshipsof pages 7-9, zain2021structurefunctionrelationshipsof pages 9-9).



References

1. (buggy2012brutontyrosinekinase pages 1-3): Joseph J. Buggy and Laurence Elias. Bruton tyrosine kinase (btk) and its role in b-cell malignancy. International Reviews of Immunology, 31:119-132, Mar 2012. URL: https://doi.org/10.3109/08830185.2012.664797, doi:10.3109/08830185.2012.664797. This article has 290 citations and is from a peer-reviewed journal.

2. (buggy2012brutontyrosinekinase pages 11-12): Joseph J. Buggy and Laurence Elias. Bruton tyrosine kinase (btk) and its role in b-cell malignancy. International Reviews of Immunology, 31:119-132, Mar 2012. URL: https://doi.org/10.3109/08830185.2012.664797, doi:10.3109/08830185.2012.664797. This article has 290 citations and is from a peer-reviewed journal.

3. (buggy2012brutontyrosinekinase pages 3-4): Joseph J. Buggy and Laurence Elias. Bruton tyrosine kinase (btk) and its role in b-cell malignancy. International Reviews of Immunology, 31:119-132, Mar 2012. URL: https://doi.org/10.3109/08830185.2012.664797, doi:10.3109/08830185.2012.664797. This article has 290 citations and is from a peer-reviewed journal.

4. (buggy2012brutontyrosinekinase pages 9-11): Joseph J. Buggy and Laurence Elias. Bruton tyrosine kinase (btk) and its role in b-cell malignancy. International Reviews of Immunology, 31:119-132, Mar 2012. URL: https://doi.org/10.3109/08830185.2012.664797, doi:10.3109/08830185.2012.664797. This article has 290 citations and is from a peer-reviewed journal.

5. (crofford2016theroleof pages 1-3): Leslie J. Crofford, Lindsay E. Nyhoff, Jonathan H. Sheehan, and Peggy L. Kendall. The role of bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Review of Clinical Immunology, 12:763-773, Mar 2016. URL: https://doi.org/10.1586/1744666x.2016.1152888, doi:10.1586/1744666x.2016.1152888. This article has 152 citations and is from a peer-reviewed journal.

6. (crofford2016theroleof pages 16-21): Leslie J. Crofford, Lindsay E. Nyhoff, Jonathan H. Sheehan, and Peggy L. Kendall. The role of bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Review of Clinical Immunology, 12:763-773, Mar 2016. URL: https://doi.org/10.1586/1744666x.2016.1152888, doi:10.1586/1744666x.2016.1152888. This article has 152 citations and is from a peer-reviewed journal.

7. (crofford2016theroleof pages 9-10): Leslie J. Crofford, Lindsay E. Nyhoff, Jonathan H. Sheehan, and Peggy L. Kendall. The role of bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Review of Clinical Immunology, 12:763-773, Mar 2016. URL: https://doi.org/10.1586/1744666x.2016.1152888, doi:10.1586/1744666x.2016.1152888. This article has 152 citations and is from a peer-reviewed journal.

8. (dinh2007activationmechanismand pages 8-8): Marie Dinh, Dorit Grunberger, Hoangdung Ho, Stan Y. Tsing, David Shaw, Simon Lee, Jim Barnett, Ronald J. Hill, David C. Swinney, and J. Michael Bradshaw. Activation mechanism and steady state kinetics of bruton's tyrosine kinase. Journal of Biological Chemistry, 282:8768-8776, Mar 2007. URL: https://doi.org/10.1074/jbc.m609920200, doi:10.1074/jbc.m609920200. This article has 61 citations and is from a domain leading peer-reviewed journal.

9. (feng2019bruton’styrosinekinase pages 1-7): Yifan Feng, Weiming Duan, Xiaochuan Cu, Chengyuan Liang, and Minhang Xin. Bruton’s tyrosine kinase (btk) inhibitors in treating cancer: a patent review (2010-2018). Expert Opinion on Therapeutic Patents, 29:217-241, Apr 2019. URL: https://doi.org/10.1080/13543776.2019.1594777, doi:10.1080/13543776.2019.1594777. This article has 65 citations and is from a peer-reviewed journal.

10. (feng2019bruton’styrosinekinase pages 25-30): Yifan Feng, Weiming Duan, Xiaochuan Cu, Chengyuan Liang, and Minhang Xin. Bruton’s tyrosine kinase (btk) inhibitors in treating cancer: a patent review (2010-2018). Expert Opinion on Therapeutic Patents, 29:217-241, Apr 2019. URL: https://doi.org/10.1080/13543776.2019.1594777, doi:10.1080/13543776.2019.1594777. This article has 65 citations and is from a peer-reviewed journal.

11. (feng2019bruton’styrosinekinase pages 43-50): Yifan Feng, Weiming Duan, Xiaochuan Cu, Chengyuan Liang, and Minhang Xin. Bruton’s tyrosine kinase (btk) inhibitors in treating cancer: a patent review (2010-2018). Expert Opinion on Therapeutic Patents, 29:217-241, Apr 2019. URL: https://doi.org/10.1080/13543776.2019.1594777, doi:10.1080/13543776.2019.1594777. This article has 65 citations and is from a peer-reviewed journal.

12. (hendriks2014targetingbrutonstyrosine pages 1-2): R. Hendriks, S. Yuvaraj, and Laurens P. Kil. Targeting bruton's tyrosine kinase in b cell malignancies. Nature Reviews Cancer, 14:219-232, Mar 2014. URL: https://doi.org/10.1038/nrc3702, doi:10.1038/nrc3702. This article has 638 citations and is from a domain leading peer-reviewed journal.

13. (hendriks2014targetingbrutonstyrosine pages 11-12): R. Hendriks, S. Yuvaraj, and Laurens P. Kil. Targeting bruton's tyrosine kinase in b cell malignancies. Nature Reviews Cancer, 14:219-232, Mar 2014. URL: https://doi.org/10.1038/nrc3702, doi:10.1038/nrc3702. This article has 638 citations and is from a domain leading peer-reviewed journal.

14. (hendriks2014targetingbrutonstyrosine pages 5-6): R. Hendriks, S. Yuvaraj, and Laurens P. Kil. Targeting bruton's tyrosine kinase in b cell malignancies. Nature Reviews Cancer, 14:219-232, Mar 2014. URL: https://doi.org/10.1038/nrc3702, doi:10.1038/nrc3702. This article has 638 citations and is from a domain leading peer-reviewed journal.

15. (kueffer2021reininginbtk pages 1-2): Lauren E. Kueffer, Raji E. Joseph, and Amy H. Andreotti. Reining in btk: interdomain interactions and their importance in the regulatory control of btk. Frontiers in Cell and Developmental Biology, Jun 2021. URL: https://doi.org/10.3389/fcell.2021.655489, doi:10.3389/fcell.2021.655489. This article has 15 citations and is from a peer-reviewed journal.

16. (kueffer2021reininginbtk pages 12-12): Lauren E. Kueffer, Raji E. Joseph, and Amy H. Andreotti. Reining in btk: interdomain interactions and their importance in the regulatory control of btk. Frontiers in Cell and Developmental Biology, Jun 2021. URL: https://doi.org/10.3389/fcell.2021.655489, doi:10.3389/fcell.2021.655489. This article has 15 citations and is from a peer-reviewed journal.

17. (liang2018thedevelopmentof pages 1-6): Chengyuan Liang, Danni Tian, Xiaodong Ren, Shunjun Ding, Minyi Jia, Minhang Xin, and Suresh Thareja. The development of bruton's tyrosine kinase (btk) inhibitors from 2012 to 2017: a mini-review. European Journal of Medicinal Chemistry, 151:315-326, May 2018. URL: https://doi.org/10.1016/j.ejmech.2018.03.062, doi:10.1016/j.ejmech.2018.03.062. This article has 198 citations and is from a domain leading peer-reviewed journal.

18. (liu2021emergingsmallmoleculeinhibitors pages 1-2): Jiakuo Liu, Chengjuan Chen, Dongmei Wang, Jie Zhang, and Tiantai Zhang. Emerging small-molecule inhibitors of the bruton’s tyrosine kinase (btk): current development. European Journal of Medicinal Chemistry, 217:113329, May 2021. URL: https://doi.org/10.1016/j.ejmech.2021.113329, doi:10.1016/j.ejmech.2021.113329. This article has 62 citations and is from a domain leading peer-reviewed journal.

19. (liu2021emergingsmallmoleculeinhibitors pages 22-23): Jiakuo Liu, Chengjuan Chen, Dongmei Wang, Jie Zhang, and Tiantai Zhang. Emerging small-molecule inhibitors of the bruton’s tyrosine kinase (btk): current development. European Journal of Medicinal Chemistry, 217:113329, May 2021. URL: https://doi.org/10.1016/j.ejmech.2021.113329, doi:10.1016/j.ejmech.2021.113329. This article has 62 citations and is from a domain leading peer-reviewed journal.

20. (lou2012bruton’styrosinekinase pages 9-10): Yan Lou, Timothy D. Owens, Andreas Kuglstatter, Rama K. Kondru, and David M. Goldstein. Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and b cell malignancies. Journal of Medicinal Chemistry, 55:4539-4550, Mar 2012. URL: https://doi.org/10.1021/jm300035p, doi:10.1021/jm300035p. This article has 148 citations and is from a highest quality peer-reviewed journal.

21. (marcotte2010structuresofhuman pages 1-3): Douglas J. Marcotte, Yu‐Ting Liu, Robert M. Arduini, Catherine A. Hession, Konrad Miatkowski, Craig P. Wildes, Patrick F. Cullen, Victor Hong, Brian T. Hopkins, Elisabeth Mertsching, Tracy J. Jenkins, Michael J. Romanowski, Darren P. Baker, and Laura F. Silvian. Structures of human bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for tec family kinases. Protein Science, Mar 2010. URL: https://doi.org/10.1002/pro.321, doi:10.1002/pro.321. This article has 170 citations and is from a peer-reviewed journal.

22. (mcdonald2021theroleof pages 1-2): Charlotte McDonald, Charalampos Xanthopoulos, and Efterpi Kostareli. The role of bruton's tyrosine kinase in the immune system and disease. Immunology, 164:722-736, Oct 2021. URL: https://doi.org/10.1111/imm.13416, doi:10.1111/imm.13416. This article has 102 citations and is from a peer-reviewed journal.

23. (mcdonald2021theroleof pages 2-5): Charlotte McDonald, Charalampos Xanthopoulos, and Efterpi Kostareli. The role of bruton's tyrosine kinase in the immune system and disease. Immunology, 164:722-736, Oct 2021. URL: https://doi.org/10.1111/imm.13416, doi:10.1111/imm.13416. This article has 102 citations and is from a peer-reviewed journal.

24. (mcdonald2021theroleof pages 22-25): Charlotte McDonald, Charalampos Xanthopoulos, and Efterpi Kostareli. The role of bruton's tyrosine kinase in the immune system and disease. Immunology, 164:722-736, Oct 2021. URL: https://doi.org/10.1111/imm.13416, doi:10.1111/imm.13416. This article has 102 citations and is from a peer-reviewed journal.

25. (mcdonald2021theroleof pages 5-7): Charlotte McDonald, Charalampos Xanthopoulos, and Efterpi Kostareli. The role of bruton's tyrosine kinase in the immune system and disease. Immunology, 164:722-736, Oct 2021. URL: https://doi.org/10.1111/imm.13416, doi:10.1111/imm.13416. This article has 102 citations and is from a peer-reviewed journal.

26. (ratzon2017asmallmolecule pages 11-12): Einav Ratzon, Itai Bloch, Meshel Nicola, Elad Cohen, Nili Ruimi, Nesly Dotan, Meytal Landau, and Maayan Gal. A small molecule inhibitor of bruton’s tyrosine kinase involved in b-cell signaling. ACS Omega, 2:4398-4410, Aug 2017. URL: https://doi.org/10.1021/acsomega.7b00576, doi:10.1021/acsomega.7b00576. This article has 10 citations and is from a peer-reviewed journal.

27. (ringheim2021bruton’styrosinekinase pages 1-2): Garth E. Ringheim, Matthew Wampole, and Kinsi Oberoi. Bruton’s tyrosine kinase (btk) inhibitors and autoimmune diseases: making sense of btk inhibitor specificity profiles and recent clinical trial successes and failures. Frontiers in Immunology, Nov 2021. URL: https://doi.org/10.3389/fimmu.2021.662223, doi:10.3389/fimmu.2021.662223. This article has 103 citations and is from a peer-reviewed journal.

28. (rozkiewicz2023bruton’styrosinekinase pages 1-3): Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, and Dariusz Pawlak. Bruton’s tyrosine kinase inhibitors (btkis): review of preclinical studies and evaluation of clinical trials. Molecules, 28:2400, Mar 2023. URL: https://doi.org/10.3390/molecules28052400, doi:10.3390/molecules28052400. This article has 58 citations and is from a peer-reviewed journal.

29. (rozkiewicz2023bruton’styrosinekinase pages 14-15): Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, and Dariusz Pawlak. Bruton’s tyrosine kinase inhibitors (btkis): review of preclinical studies and evaluation of clinical trials. Molecules, 28:2400, Mar 2023. URL: https://doi.org/10.3390/molecules28052400, doi:10.3390/molecules28052400. This article has 58 citations and is from a peer-reviewed journal.

30. (rozkiewicz2023bruton’styrosinekinase pages 3-5): Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, and Dariusz Pawlak. Bruton’s tyrosine kinase inhibitors (btkis): review of preclinical studies and evaluation of clinical trials. Molecules, 28:2400, Mar 2023. URL: https://doi.org/10.3390/molecules28052400, doi:10.3390/molecules28052400. This article has 58 citations and is from a peer-reviewed journal.

31. (rozkiewicz2023bruton’styrosinekinase pages 5-6): Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, and Dariusz Pawlak. Bruton’s tyrosine kinase inhibitors (btkis): review of preclinical studies and evaluation of clinical trials. Molecules, 28:2400, Mar 2023. URL: https://doi.org/10.3390/molecules28052400, doi:10.3390/molecules28052400. This article has 58 citations and is from a peer-reviewed journal.

32. (schnute2012brutonstyrosinekinase pages 1-3): MARK E. SCHNUTE, ADRIAN HUANG, and EDDINE SAIAH. Bruton's tyrosine kinase (btk). Anti-Inflammatory Drug Discovery, pages 297-326, Jul 2012. URL: https://doi.org/10.1039/9781849735346-00297, doi:10.1039/9781849735346-00297. This article has 3 citations.

33. (schnute2012brutonstyrosinekinase pages 25-27): MARK E. SCHNUTE, ADRIAN HUANG, and EDDINE SAIAH. Bruton's tyrosine kinase (btk). Anti-Inflammatory Drug Discovery, pages 297-326, Jul 2012. URL: https://doi.org/10.1039/9781849735346-00297, doi:10.1039/9781849735346-00297. This article has 3 citations.

34. (schnute2012brutonstyrosinekinase pages 3-6): MARK E. SCHNUTE, ADRIAN HUANG, and EDDINE SAIAH. Bruton's tyrosine kinase (btk). Anti-Inflammatory Drug Discovery, pages 297-326, Jul 2012. URL: https://doi.org/10.1039/9781849735346-00297, doi:10.1039/9781849735346-00297. This article has 3 citations.

35. (schnute2012brutonstyrosinekinase pages 8-11): MARK E. SCHNUTE, ADRIAN HUANG, and EDDINE SAIAH. Bruton's tyrosine kinase (btk). Anti-Inflammatory Drug Discovery, pages 297-326, Jul 2012. URL: https://doi.org/10.1039/9781849735346-00297, doi:10.1039/9781849735346-00297. This article has 3 citations.

36. (singh2018roleofbruton’s pages 1-2): Simar Pal Singh, Floris Dammeijer, and Rudi W. Hendriks. Role of bruton’s tyrosine kinase in b cells and malignancies. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0779-z, doi:10.1186/s12943-018-0779-z. This article has 772 citations and is from a highest quality peer-reviewed journal.

37. (singh2018roleofbruton’s pages 17-17): Simar Pal Singh, Floris Dammeijer, and Rudi W. Hendriks. Role of bruton’s tyrosine kinase in b cells and malignancies. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0779-z, doi:10.1186/s12943-018-0779-z. This article has 772 citations and is from a highest quality peer-reviewed journal.

38. (singh2018roleofbruton’s pages 2-4): Simar Pal Singh, Floris Dammeijer, and Rudi W. Hendriks. Role of bruton’s tyrosine kinase in b cells and malignancies. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0779-z, doi:10.1186/s12943-018-0779-z. This article has 772 citations and is from a highest quality peer-reviewed journal.

39. (weber2017bruton’styrosinekinase pages 1-2): Alexander N. R. Weber, Zsofia Bittner, Xiao Liu, Truong-Minh Dang, Markus Philipp Radsak, and Cornelia Brunner. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Frontiers in Immunology, Nov 2017. URL: https://doi.org/10.3389/fimmu.2017.01454, doi:10.3389/fimmu.2017.01454. This article has 288 citations and is from a peer-reviewed journal.

40. (weber2017bruton’styrosinekinase pages 2-4): Alexander N. R. Weber, Zsofia Bittner, Xiao Liu, Truong-Minh Dang, Markus Philipp Radsak, and Cornelia Brunner. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Frontiers in Immunology, Nov 2017. URL: https://doi.org/10.3389/fimmu.2017.01454, doi:10.3389/fimmu.2017.01454. This article has 288 citations and is from a peer-reviewed journal.

41. (wen2021inhibitorstargetingbruton’s pages 1-2): Tingyu Wen, Jinsong Wang, Yuankai Shi, Haili Qian, and Peng Liu. Inhibitors targeting bruton’s tyrosine kinase in cancers: drug development advances. Leukemia, 35:312-332, Oct 2021. URL: https://doi.org/10.1038/s41375-020-01072-6, doi:10.1038/s41375-020-01072-6. This article has 253 citations and is from a highest quality peer-reviewed journal.

42. (whang2014brutonstyrosinekinase pages 1-3): Jennifer A. Whang and Betty Y. Chang. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discovery Today, 19:1200-1204, Aug 2014. URL: https://doi.org/10.1016/j.drudis.2014.03.028, doi:10.1016/j.drudis.2014.03.028. This article has 145 citations and is from a domain leading peer-reviewed journal.

43. (xing2014brutonstkinhibitors pages 1-2): Li Xing and Adrian Huang. Bruton's tk inhibitors: structural insights and evolution of clinical candidates. Future medicinal chemistry, 6 6:675-95, Jun 2014. URL: https://doi.org/10.4155/fmc.14.24, doi:10.4155/fmc.14.24. This article has 13 citations and is from a peer-reviewed journal.

44. (xing2014brutonstkinhibitors pages 16-18): Li Xing and Adrian Huang. Bruton's tk inhibitors: structural insights and evolution of clinical candidates. Future medicinal chemistry, 6 6:675-95, Jun 2014. URL: https://doi.org/10.4155/fmc.14.24, doi:10.4155/fmc.14.24. This article has 13 citations and is from a peer-reviewed journal.

45. (xing2014brutonstkinhibitors pages 18-19): Li Xing and Adrian Huang. Bruton's tk inhibitors: structural insights and evolution of clinical candidates. Future medicinal chemistry, 6 6:675-95, Jun 2014. URL: https://doi.org/10.4155/fmc.14.24, doi:10.4155/fmc.14.24. This article has 13 citations and is from a peer-reviewed journal.

46. (xing2014brutonstkinhibitors pages 19-20): Li Xing and Adrian Huang. Bruton's tk inhibitors: structural insights and evolution of clinical candidates. Future medicinal chemistry, 6 6:675-95, Jun 2014. URL: https://doi.org/10.4155/fmc.14.24, doi:10.4155/fmc.14.24. This article has 13 citations and is from a peer-reviewed journal.

47. (xing2014brutonstkinhibitors pages 2-3): Li Xing and Adrian Huang. Bruton's tk inhibitors: structural insights and evolution of clinical candidates. Future medicinal chemistry, 6 6:675-95, Jun 2014. URL: https://doi.org/10.4155/fmc.14.24, doi:10.4155/fmc.14.24. This article has 13 citations and is from a peer-reviewed journal.

48. (zain2021structurefunctionrelationshipsof pages 1-2): Rula Zain and Mauno Vihinen. Structure-function relationships of covalent and non-covalent btk inhibitors. Frontiers in Immunology, Jul 2021. URL: https://doi.org/10.3389/fimmu.2021.694853, doi:10.3389/fimmu.2021.694853. This article has 57 citations and is from a peer-reviewed journal.

49. (zain2021structurefunctionrelationshipsof pages 7-9): Rula Zain and Mauno Vihinen. Structure-function relationships of covalent and non-covalent btk inhibitors. Frontiers in Immunology, Jul 2021. URL: https://doi.org/10.3389/fimmu.2021.694853, doi:10.3389/fimmu.2021.694853. This article has 57 citations and is from a peer-reviewed journal.

50. (zain2021structurefunctionrelationshipsof pages 9-9): Rula Zain and Mauno Vihinen. Structure-function relationships of covalent and non-covalent btk inhibitors. Frontiers in Immunology, Jul 2021. URL: https://doi.org/10.3389/fimmu.2021.694853, doi:10.3389/fimmu.2021.694853. This article has 57 citations and is from a peer-reviewed journal.